Company: DARE
Filing Date: 2025-04-24
Form Type: ARS
Source: 0001401914-25-000018
Chunk: 244

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: ARS
Chunk 244
---
 $3.0 million in general and administrative expenses from 2023 to 2024 was primarily attributable to decreases in (i) commercial-readiness expenses of approximately $1.6 million, (ii) personnel costs of approximately $0.6 million due to reduced headcount, (iii) stock-based compensation expense of approximately $0.3 million, (iv) a one-time fraud loss in the first quarter of 2023 of approximately $0.2 million, net of proceeds we received under an insurance policy, related to criminal fraud commonly referred to as "business email compromise fraud" to which we were subject, and (v) professional services expenses of approximately $0.2 million. Research and development expenses The following table summarizes our R&D expenses for the periods indicated, together with the changes in those items in terms of dollars and percentage: 125

Years Ended December 31, Change 2024 2023 $ % Direct program costs: Ovaprene (1) $ 8,518,495 $ 3,762,611 $ 4,755,884 126 % Sildenafil Cream, 3.6% 2,361,052 7,746,264 (5,385,212) (70) % Other advanced clinical stage programs 1,321,888 3,498,955 (2,177,067) (62) % Phase 1 and Phase 1-ready clinical stage programs (1) 761,721 2,912,857 (2,151,136) (74) % Preclinical stage programs (1) 4,233,762 7,432,439 (3,198,677) (43) % Other development programs 27,542 189,706 (162,164) (85) % Contra R&D expenses (2) (7,685,533) (8,965,347) 1,279,814 (14) % Total direct program costs 9,538,927 16,577,485 (7,038,558) (42) % Indirect costs: Personnel-related (including stock compensation) 5,611,057 5,566,016 45,041 1 % Outside services (including consulting) 543 38,114 (37,571) (99) % Facilities-related (including depreciation) 78,168 86,239 (8,071) (9) % Other indirect R&D costs 176,061